Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.90
+2.3%
$5.02
$4.00
$7.54
$328.21M1.351.07 million shs852,657 shs
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.05
+1.4%
$14.65
$9.98
$20.90
$308.73M0.8187,323 shs43,165 shs
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$0.95
+2.7%
$0.85
$0.64
$7.29
$90.38M0.661.04 million shs901,994 shs
Organogenesis stock logo
ORGO
Organogenesis
$2.37
-6.3%
$2.56
$2.04
$7.08
$325.55M1.311.38 million shs2.97 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-3.99%+5.68%+19.96%+12.48%+9.53%
Amarin Corporation PLC stock logo
AMRN
Amarin
-0.40%+6.53%+1.02%+0.61%+45.06%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-10.94%+14.17%+15.94%+2.54%-70.83%
Organogenesis stock logo
ORGO
Organogenesis
-1.76%+7.02%+11.28%-33.29%-51.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.90
+2.3%
$5.02
$4.00
$7.54
$328.21M1.351.07 million shs852,657 shs
Amarin Corporation PLC stock logo
AMRN
Amarin
$15.05
+1.4%
$14.65
$9.98
$20.90
$308.73M0.8187,323 shs43,165 shs
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$0.95
+2.7%
$0.85
$0.64
$7.29
$90.38M0.661.04 million shs901,994 shs
Organogenesis stock logo
ORGO
Organogenesis
$2.37
-6.3%
$2.56
$2.04
$7.08
$325.55M1.311.38 million shs2.97 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-3.99%+5.68%+19.96%+12.48%+9.53%
Amarin Corporation PLC stock logo
AMRN
Amarin
-0.40%+6.53%+1.02%+0.61%+45.06%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-10.94%+14.17%+15.94%+2.54%-70.83%
Organogenesis stock logo
ORGO
Organogenesis
-1.76%+7.02%+11.28%-33.29%-51.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
2.60
Moderate Buy$19.00222.03% Upside
Amarin Corporation PLC stock logo
AMRN
Amarin
2.00
Hold$12.00-20.27% Downside
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.00
Hold$25.672,612.32% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.33
Hold$8.50258.65% Upside

Current Analyst Ratings Breakdown

Latest ATYR, ABEO, ORGO, and AMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2026
Organogenesis stock logo
ORGO
Organogenesis
DowngradeBuyNeutral
4/20/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Reiterated RatingSell (D-)
4/2/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
UpgradeHoldStrong-Buy
3/26/2026
Organogenesis stock logo
ORGO
Organogenesis
Reiterated RatingBuy$8.00
3/19/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Reiterated RatingBuy$20.00
3/17/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Set Price Target$17.00
3/10/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Reiterated RatingBuy$20.00
3/9/2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Reiterated RatingOutperform
3/6/2026
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Reiterated RatingBuy
3/4/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
UpgradeStrong SellHold
2/27/2026
Organogenesis stock logo
ORGO
Organogenesis
UpgradeSell (D+)Hold (C)
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.82M57.66N/AN/A$2.94 per share2.01
Amarin Corporation PLC stock logo
AMRN
Amarin
$213.65M1.47$0.37 per share41.11$21.60 per share0.70
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$190K488.35N/AN/A$0.69 per share1.37
Organogenesis stock logo
ORGO
Organogenesis
$564.17M0.54$0.61 per share3.91$2.36 per share1.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$71.18M$1.035.7332.78N/AN/A-60.65%-40.78%5/13/2026 (Estimated)
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%N/A
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$74.12M-$0.79N/AN/AN/AN/A-99.87%-74.41%N/A
Organogenesis stock logo
ORGO
Organogenesis
$37.03M$0.08N/AN/AN/A-0.84%9.47%4.76%N/A

Latest ATYR, ABEO, ORGO, and AMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.34N/AN/AN/A$4.57 millionN/A
5/7/2026Q1 2026
Organogenesis stock logo
ORGO
Organogenesis
-$0.29-$0.44-$0.15-$0.44$43.26 million$37.23 million
3/17/2026Q4 2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.35-$0.34+$0.01-$0.34$5.65 million$3.00 million
3/5/2026Q4 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18-$0.14+$0.04-$0.14$0.02 millionN/A
2/26/2026Q4 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.21$0.31+$0.10$0.24$172.68 million$225.61 million
2/25/2026Q4 2025
Amarin Corporation PLC stock logo
AMRN
Amarin
-$1.27$0.01+$1.28N/A$50.62 million$49.22 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.05
6.93
6.74
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.48
2.46
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/A
5.30
5.30
Organogenesis stock logo
ORGO
Organogenesis
0.04
3.62
3.32

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
Organogenesis stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
6.90%
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5.75%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
9056.88 million52.96 millionOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
36020.80 million19.93 millionOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5398.05 million92.41 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950128.68 million86.21 millionOptionable

Recent News About These Companies

Organogenesis Q1 Earnings Call Highlights
Organogenesis Holdings, Inc. Class A
Why is Organogenesis Stock (ORGO) Up 20% Today?
Organogenesis stock surges 20% on trial results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$5.90 +0.13 (+2.25%)
Closing price 04:00 PM Eastern
Extended Trading
$5.88 -0.02 (-0.31%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Amarin stock logo

Amarin NASDAQ:AMRN

$15.05 +0.21 (+1.42%)
Closing price 04:00 PM Eastern
Extended Trading
$14.93 -0.12 (-0.80%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$0.95 +0.02 (+2.66%)
Closing price 04:00 PM Eastern
Extended Trading
$0.93 -0.01 (-1.51%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.37 -0.16 (-6.32%)
Closing price 04:00 PM Eastern
Extended Trading
$2.38 +0.01 (+0.38%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.